APG-115-US-002
29 Nov 2021
APG-115-US-002
NCT03611868
A Phase Ib/II Study of APG-115 in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Ascentage Pharma Group Inc
Cancer Type | Melanoma & other skin, Other |
---|---|
Trial Type | Treatment |
Phase | Phase I, Phase II |
Age Range | 12 Years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | Locally Advanced, Metastatic or Widespread |
Anticipated Start Date | 2018-07-29 |
Anticipated End Date | 2022-10-30 |
Hospital | Flinders Medical Centre |
---|---|
Clinical Trial Coordinator | Hannah Adelson |
Hannah.adelson@sa.gov.au | |
Phone | 08 8206 4835 |
Principal Investigator | Professor Chris Karapetis |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs